HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place...
Hence then, the article about ivonescimab first line biliary tract cancer phase iii overall survival data selected as esmo late breaking abstract nearly 30 akeso studies to be presented at esmo 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026 )
Also on site :
- Meta May Try to Repair Its Poor Privacy Reputation at 'Connect 2026'
- ‘Forgotten Island’ Review: H.E.R. And Dave Franco Give Life To Gorgeously Animated And Frenetic ‘Toon
- Princess Diana’s Brother Reveals What Bombshell Claims About King Charles Won’t ‘Be a Surprise’ to William & Harry